- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02077465
Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)
August 21, 2020 updated by: Gilead Sciences
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
The primary objective of the study is to assess the safety and tolerability of multiple infusions of andecaliximab (formerly GS-5745) in participants with chronic obstructive pulmonary disease (COPD) as assessed by adverse events (AEs) and laboratory abnormalities.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33169
- Elite Research Institute
-
Miami, Florida, United States, 33136
- Advanced Pharma Cr, Llc
-
Orlando, Florida, United States, 32806
- Compass Research, LLC
-
-
New York
-
Buffalo, New York, United States, 14203
- University at Buffalo CTRC
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- Volunteer Research Group
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Weight: ≥ 45 kg to < 120 kg at screening
- Males or non-pregnant, non-lactating females
- Male individuals and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception. Male individuals must refrain from sperm donation for 90 days post last infusion of the study drug
- Diagnosis of COPD per Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for at least 6 months prior to screening and anticipated to remain on stable therapy for the duration of the study
- Post-bronchodilator forced expiratory volume in one second (FEV1) ≥ 40% predicted
- No changes in COPD medications within 30 days prior to randomization
- Hepatic panel [aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, alkaline phosphatase, lactate dehydrogenase (LDH)] ≤ 2 times the upper limit of the normal range (ULN)
- Serum creatinine ≤ 2.0
- Hemoglobin ≥ 8.5 g/dL (both males and females)
- Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L (1,500 mm^3)
- Platelets ≥ 100 x 10^9/L
Key Exclusion Criteria:
- Clinically significant active infection as judged by the investigator during screening
- Known history of HIV, hepatitis B or C during screening. Individuals who are hepatitis B surface antigen positive, but who received a successful series of hepatitis B vaccinations and never had the disease remain eligible
- A positive QuantiFERON-TB GOLD test during screening
- History of malignancy within the last 5 years except for patients who have been treated locally for non-melanoma skin cancer or cervical carcinoma in situ
- Any serious cardiac event such as myocardial infarction, unstable or life-threatening arrhythmia, hospitalization for cardiac failure within 6 months prior to randomization or any significant or new electrocardiogram (ECG) finding at Visit 1 as judged by the Investigator
- A hospitalization for a respiratory event such as, but not limited to, COPD, pneumonia, bronchiolitis, within the previous 6 months prior to randomization
- Chronic lung disease other than COPD such as: asthma, cystic fibrosis or fibrotic disease, α-1-antitrypsin deficiency, interstitial lung disease, pulmonary thromboembolic disease, or bronchiectasis
- Chronic use of systemic corticosteroids and/or treatment with systemic corticosteroids for an acute exacerbation of COPD (AECOPD) event, or other medical condition not requiring hospitalization, within 90 days of randomization.
- Treatment with antibiotics for an AECOPD event, or other medical condition not requiring hospitalization within 90 days of randomization, or any minor medical event not requiring hospitalization within 14 days of randomization.
- Treatment with any marketed or investigational biologic within 5 half-lives of the molecule or if unknown within 90 days of screening
- Individuals currently on nonbiologic immune modulator medications such as: azathioprine, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, mycophenolate mofetil, sulfasalazine, tofacitinib, within 90 days of randomization
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Andecaliximab
Participants will receive andecaliximab every 2 weeks for a total of 3 infusions.
|
400 mg andecaliximab administered intravenously
Other Names:
|
Placebo Comparator: Placebo to match andecaliximab
Participants will receive placebo to match andecaliximab every 2 weeks for a total of 3 infusions.
|
Placebo to match andecaliximab administered intravenously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
Time Frame: First dose date up to Day 29 plus 30 days
|
First dose date up to Day 29 plus 30 days
|
|
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities
Time Frame: First dose date up to Day 29 plus 30 days
|
A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from baseline and occurring after the first dose of study drug and within 30 days after last study drug administration.
The severity of laboratory abnormalities was assessed as Grade 0, 1 (mild), 2 (moderate), 3 (severe), or 4 (potentially life threatening) using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.
The most severe graded abnormality from all tests was counted for each participant.
|
First dose date up to Day 29 plus 30 days
|
Percentage of Participants Who Developed Anti-andecaliximab Antibodies
Time Frame: Day 43
|
The presence of anti-andecaliximab antibodies in serum samples was determined using an electrochemiluminescent (ECL) assay that detects antibodies that bind to andecaliximab.
|
Day 43
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic (PK) Parameter of Andecaliximab: AUClast for Days 1, 15 and 29
Time Frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes
|
AUClast is defined as the area under the plasma concentration versus time curve from time zero to the last quantifiable concentration.
Data for Day 1 was generated based on the data collected from Day 1 through Day 15.
Data for Day 15 was generated based on the data collected from Day 15 through Day 29.
Data for Day 29 was generated based on the data collected from Day 29 through Day 43.
|
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes
|
PK Parameter of Andecaliximab: AUCinf for Day 1
Time Frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
|
AUCinf is defined as the area under the plasma concentration versus time curve extrapolated to infinite time.
Data for Day 1 was generated based on the data collected from Day 1 through Day 15.
|
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
|
PK Parameter of Andecaliximab: %AUCexp for Day 1
Time Frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
|
%AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf.
Data for Day 1 was generated based on the data collected from Day 1 through Day 15.
|
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
|
PK Parameter of Andecaliximab: Cmax for Days 1, 15 and 29
Time Frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes
|
Cmax is defined as the maximum observed plasma concentration of drug.
Data for Day 1 was generated based on the data collected from Day 1 through Day 15.
Data for Day 15 was generated based on the data collected from Day 15 through Day 29.
Data for Day 29 was generated based on the data collected from Day 29 through Day 43.
|
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes
|
PK Parameter of Andecaliximab: Tmax for Days 1, 15 and 29
Time Frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes
|
Tmax is defined as the time (observed time point) of Cmax.
Data for Day 1 was generated based on the data collected from Day 1 through Day 15.
Data for Day 15 was generated based on the data collected from Day 15 through Day 29.
Data for Day 29 was generated based on the data collected from Day 29 through Day 43.
|
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes
|
PK Parameter of Andecaliximab: Clast for Days 1, 15 and 29
Time Frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes
|
Clast is defined as the last observable concentration of drug.
Data for Day 1 was generated based on the data collected from Day 1 through Day 15.
Data for Day 15 was generated based on the data collected from Day 15 through Day 29.
Data for Day 29 was generated based on the data collected from Day 29 through Day 43.
|
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes
|
PK Parameter of Andecaliximab: Tlast for Days 1, 15 and 29
Time Frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes
|
Tlast is defined as the time (observed time point) of Clast.
Data for Day 1 was generated based on the data collected from Day 1 through Day 15.
Data for Day 15 was generated based on the data collected from Day 15 through Day 29.
Data for Day 29 was generated based on the data collected from Day 29 through Day 43.
|
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day3, Day 8, Day 15 (pre-infusion; and 30 minutes post end of infusion), Day 29 (pre-infusion; and 30 minutes post end of infusion), Day 36 and Day 43; Infusion duration = 30 to 35 minutes
|
PK Parameter of Andecaliximab: λz for Day 1
Time Frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
|
λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.
Data for Day 1 was generated based on the data collected from Day 1 through Day 15.
|
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
|
PK Parameter of Andecaliximab: CL for Day 1
Time Frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
|
Clearance (CL) is defined as the systemic clearance of the drug following intravenous administration.
Data for Day 1 was generated based on the data collected from Day 1 through Day 15.
|
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
|
PK Parameter of Andecaliximab: Vz for Day 1
Time Frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
|
Vz is defined as the volume of distribution of the drug after intravenous administration.
Data for Day 1 was generated based on the data collected from Day 1 through Day 15.
|
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
|
PK Parameter of Andecaliximab: Vss for Day 1
Time Frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
|
Vss is defined as the volume of distribution of the drug at steady state after intravenous administration.
Data for Day 1 was generated based on the data collected from Day 1 through Day 15.
|
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
|
PK Parameter of Andecaliximab: t1/2 for Day 1
Time Frame: Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
|
t1/2 is defined as the estimate of the terminal elimination half-life of the drug.
Data for Day 1 was generated based on the data collected from Day 1 through Day 15.
|
Day 1 (pre-infusion; 30 minutes and 4 hours post end of infusion), Day 3, Day 8, and Day 15 (pre-infusion); Infusion duration = 30 minutes to 35 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 11, 2014
Primary Completion (Actual)
October 27, 2014
Study Completion (Actual)
October 27, 2014
Study Registration Dates
First Submitted
February 28, 2014
First Submitted That Met QC Criteria
March 3, 2014
First Posted (Estimate)
March 4, 2014
Study Record Updates
Last Update Posted (Actual)
September 9, 2020
Last Update Submitted That Met QC Criteria
August 21, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GS-US-368-1212
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Andecaliximab
-
Gilead SciencesTerminatedCrohn's DiseaseSpain, United Kingdom, United States, France, Italy, Germany, New Zealand, Australia, Poland, South Africa, Hungary, Canada, Czechia
-
Gilead SciencesTerminatedCystic FibrosisFrance, Germany, Spain, United Kingdom, Australia
-
Gilead SciencesTerminatedUlcerative ColitisUnited States, Australia, France, Poland, Ukraine, Switzerland, Romania, Canada, Netherlands, Korea, Republic of, Belgium, Russian Federation, Taiwan, New Zealand, Hungary, United Kingdom, Bulgaria, Latvia, Czechia, Slovakia, Italy and more
-
Gilead SciencesCompletedUlcerative ColitisUnited States, Belgium, Netherlands, Canada, Hungary, Moldova, Republic of, Romania
-
Gilead SciencesCompletedGastric Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaSpain, United States, Hungary, United Kingdom, Italy, France, Poland, Australia, Belgium
-
Gilead SciencesTerminated
-
Gilead SciencesCompletedGastric AdenocarcinomaSpain, United States, United Kingdom, Turkey, France, Germany, Chile, Australia, Colombia, Czechia, Belgium, Hungary, Italy, Peru, Poland, Romania
-
Gilead SciencesTerminated
-
Gilead SciencesCompletedBreast Cancer | Colorectal Cancer | Pancreatic Cancer | Non-small Cell Lung Cancer | Esophagogastric CancerUnited States